First Trust, one of the largest issuers of US ETFs, terminated TCW Group Inc. as the manager of four exchange-traded funds ...

Assetmark Inc. grew its position in Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA – Free Report) by 16.6% in the ...

Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...

Sideshow and Janus Films have unveiled a five U.S. cities tour for Alain Guiraudie’s Misericordia later this month. After ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as ...

There are many criticisms you can level at the investment industry, keepers of our pension funds and stocks and shares ...

EverCommerce (NASDAQ:EVCM – Free Report) had its price target reduced by Oppenheimer from $13.00 to $12.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Six analysts round out the team, which saw several changes in recent years, including the departure ... today's asset-management industry or brand new to Janus Henderson—its former CEO espoused ...